Our incredible special guest tonight is Dr. Diana Rosas, MD, Director, Center for Neuro-Imaging of Aging and Neurodegenerative Disease. Dr. Rosas and her team have focused primarily on the development of biomarkers for use in the study of neurodegenerative diseases, to better characterize progression, to better understand genotype/phenotype correlations and to apply novel neuroimaging approaches in clinical trials with the overall aim of making them more efficient.
Dr. Rosas’ lab has begun to develop models that may explain clinically heterogeneous phenotypes and variability in disease progression. The current models for both disease prediction and prediction of disease progression are insensitive and inaccurate. Dr. Rosas is planning to expand her efforts to include multi-modal and multi-spectral imaging approaches that promise both more precise measurements and may provide novel and important information on the neural underpinnings of HD and their clinical consequences.
Dr. Rosas is Co-Principal Investigator for the CREST-E Study. CREST-E stands for Creatine Safety, Tolerability, & Efficacy in Huntington’s disease. The Huntington Study Group (HSG), in a partnership between Massachusetts General Hospital (MGH) and the University of Rochester, is conducting a global, multi-center, randomized, double-blind, placebo-controlled clinical trial in individuals 18 years of and older with Huntington’s disease (HD). Tonight is the third and final episode in the CREST-E Series. Tune in for another amazing episode about CREST-E.
Contact Dr. Diana Rosas
Sorry we couldn't complete your registration. Please try again.
Please enter your email to finish creating your account.
Receive a personalized list of podcasts based on your preferences.